Genetic testing and Alzheimer disease: Recommendations of the Stanford Program in Genomics, Ethics, and Society

Genetic Testing

Volumn 3, Issue 1, 1999, Pages 3-12

  McConnell, Laura M ^a   Koenig, Barbara A ^a,b,g   Greely, Henry T ^a,c   Raffin, Thomas A ^a   Caulfield, Timothy ⁱ   Chandra, Ravi ⁱ   Chun, Nicki ⁱ   Coon, David ⁱ   Davies, Helen ⁱ   Dembitzer, Anne ⁱ   Eaton, Margaret ⁱ   Edgerly, Elizabeth ⁱ   Eswara, Marthand ⁱ   Fogarty, Mignon ⁱ   Fox, Patrick ^h   Gallagher Thompson, Dolores ⁱ   Goldstein, Mary ⁱ   Hirtle, Marie ⁱ   Holtzman, Samuel ⁱ   Horsma, H Geraldine ^d   Hurlbut, William ⁱ   Kaplan, Jonathan ^e   Kelly, Susan ⁱ   Klepper, Howard ⁱ   Kobori, Joyce ⁱ   Lam, Eu Meng ⁱ   Logan, Beth ⁱ   Mortiz, Deborah ⁱ   Neidich, Julie Ann ⁱ   Powell, Traci ⁱ   Rorty, Mary ⁱ   Silverberg, Heather ⁱ   Silvers, Anita ⁱ   Stefanac, Susan ⁱ   Stockdale, Alan ^f   Thaler, Michael ^h   Tobin, Sara ⁱ   Yeo, Gwen ⁱ   more..

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD LAW SCHOOL   (United States)

^d Gunn High School   (United States)

^e UNIVERSITY OF TENNESSEE   (United States)

^f Ctr Appl Ethics and Prof Pract   (United States)

^g STANFORD UNIVERSITY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; GENE LOCATION; GENE MAPPING; HUMAN; MEDICAL ETHICS; MEDICAL SOCIETY; MOLECULAR CLONING; REVIEW;

EID: 0032965722     PISSN: 10906576     EISSN: None     Source Type: Journal    
DOI: 10.1089/gte.1999.3.3     Document Type: Review

References (36)

1. AAAS, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE. (1993). Benchmarks for Science Literacy. (Oxford University Press, Oxford).
2. AMERICAN COLLEGE OF MEDICAL GENETICS, AMERICAN SOCIETY OF HUMAN GENETICS, AND WORKING GROUP ON APOE AND ALZHEIMER DISEASE. (1995). Statement on use of apolipoprotein E testing for Alzheimer disease. J. Am. Med. Assn. 274, 1627-1629.
3. CAULFIELD, T.A. (1999). The law, adolescents, and the APOE4 genotype: A view from Canada. Genet. Testing 3, 107-113.
4. COON, D.W., and EDGERLY, E.S. (1999). The personal and social consequences of Alzheimer disease. Genet. Testing 3, 29-36.
5. COON, D.W., DAVIES, H., McKIBBIN, C., GALLAGHER-THOMPSON, D. (1999). The psychological impact of genetic testing for Alzheimer disease. Genet. Testing 3, 121-131.
6. EATON, M.L. (1999). Surrogate decision making for genetic testing for Alzheimer disease. Genet. Testing 3, 93-97.
7. ERNST, R.L., and HAY, J.W. (1994). The US economic and social costs of Alzheimer's disease revisited. Am. J. Public Health 84, 1261-1264.
8. EVANS, D.A., SCHERR, P.A., COOK, N.R., et al. (1990). Estimated prevalence of Alzheimer's disease in the United States. Milbank Q. 68, 267-289.
9. FARRER, L.A., CUPPLES, L.A., HAINES, J.L., et al. (1997). Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. J. Am. Med. Assn. 278, 1349-1356.
10. FOGARTY, M. (1999). Genetic testing, Alzheimer disease, and long-term care insurance. Genet. Testing 3, 133-137.
11. FOX, P.J., KELLY, S.E., and TOBIN, S.L. (1999). Defining dementia: social and historical background of Alzheimer disease. Genet. Testing 3, 13-19.
12. GREELY, H.T. (1999). Special issues in genetic testing for Alzheimer disease. Genet. Testing 3, 115-119.
13. HOLTZMAN, N.A., and WATSON, M.S. (1997). Promoting Safe and Effective Genetic Testing in the United States: Final Report of the Task Force on Genetic Testing. National Institutes of Health, Washington, DC.
14. HOLTZMAN, S., OZANNE, E., CARONE, B., et al. (1999). Decision analysis and Alzheimer disease: three case studies. Genet. Testing 3, 71-83.
15. HORSMA, G. (1999). High school genetics education and Alzheimer disease. Genet. Testing 3, 147-153.
16. KAPLAN, J.M. (1999). A philosophical critique of decision analysis as a tool in genetic testing. Genet. Testing 3, 85-91.
17. KLEPPER, H., and RORTY, M.V. (1999). Personal identity, advance directives, and genetic testing for Alzheimer disease. Genet. Testing 3, 99-106.
18. KOENIG, B.A., GREELY, H.T., McCONNELL, L.M., et al. (1998). Genetic testing for BRCA1 and BRCA2: Recommendations of the Stanford Program in Genomics, Ethics, and Society. J. Womens Health 7, 531-545.
19. KOENIG, B.A., and SILVERBERG, H.L. (1999). Understanding probabilistic risk in predisposition genetic testing for Alzheimer disease. Genet. Testing 3, 55-63.
20. LENDON, C.L., ASHALL, F., and GOATE, A.M. (1997). Exploring the etiology of Alzheimer disease using molecular genetics. J. Am. Med. Assn. 227, 825-831.
21. MAYEUX, R., SAUNDERS, A.M., SHEA, S., et al. (1998). Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. N. Engl. J. Med. 338, 506-511.
22. McCONNELL, L.M. (1999). Understanding genetic testing for Alzheimer disease: Medical and epidemiological background. Genet. Testing 3, 21-27.
23. McCONNELL, L.M., and GOLDSTEIN, M.K. (1999). The application of medical decision analysis to genetic testing: An introduction. Genet. Testing 3, 65-70.
24. McCONNELL, L.M., SANDERS, G., and OWENS, D.K. (1999). Evaluation of genetic tests: APOE genotyping for the diagnosis of Alzheimer disease. Genet. Testing 3, 47-53.
25. MEDICAL AND SCIENTIFIC ADVISORY COMMITTEE, AND ALZHEIMER'S DISEASE INTERNATIONAL. (1995). Consensus statement on predictive testing for Alzheimer disease. Alzheimer Dis. Assoc. Disord. 9, 182-187.
26. NATIONAL INSTITUTE ON AGING, AND ALZHEIMER'S ASSOCIATION WORKING GROUP. (1996). Apolipoprotein E genotyping in Alzheimer's disease. Lancet 347, 1091-1095.
27. POST, S.G., WHITEHOUSE, P.J., BINSTOCK, R.H., et al. (1997). The clinical introduction of genetic testing for Alzheimer disease: An ethical perspective. J. Am. Med. Assn. 227, 832-836.
28. RALL, S.C., and MAHLEY, R.W. (1992). The role of apolipoprotein E genetic variants in lipoprotein disorders. J. Intern. Med. 231, 653-659.
29. SCHOFIELD, P.W., TANG, M., MARDER, K., et al. (1997). Alzheimer's disease after remote head injury: an incidence study. J. Neurol. Neurosurg. Psychiatry 62, 119-124.
30. SHERRINGTON, R., ROGAEV, E.I., LIANG, Y., et al. (1995). Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375, 754-760.
31. STOCKDALE, A. (1999). Public understanding of genetics and Alzheimer disease. Genet. Testing 3, 139-145.
32. STRITTMATTER, W.J., SAUNDERS, A.M., SCHMECHEL, D., et al. (1993). Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 1977-1981.
33. TANG, M.X., MAESTRE, G., TSAI, W.Y., et al. (1996). Effect of age, ethnicity, and head injury on the association between APOE genotypes and Alzheimer's disease. Ann. N.Y. Acad. Sci. 802, 6-15.
34. TEASDALE, G.M., NICOLL, J.A.R., MURRAY, G., and FIDDES, M. (1997). Association of apolipoprotein E polymorphism with outcome after head injury. Lancet 650, 1069-1071.
35. TOBIN, S.L., CHUN, N., POWELL, T., and McCONNELL, L.M. (1999). The genetics of Alzheimer disease and the application of molecular tests. Genet. Testing 3, 37-45.
36. TVERSKY, A., and KAHNEMAN, D. (1974). Judgement under uncertainty: Heuristics and biases. Science 185, 1124-1130.